U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15N3S.2ClH
Molecular Weight 282.233
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALIPEXOLE DIHYDROCHLORIDE

SMILES

Cl.Cl.NC1=NC2=C(CCN(CC=C)CC2)S1

InChI

InChIKey=DPQAXNSOFFYKDS-UHFFFAOYSA-N
InChI=1S/C10H15N3S.2ClH/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8;;/h2H,1,3-7H2,(H2,11,12);2*1H

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8842679

Talipexole is a D2 receptor agonist which was marketed in June 1996 in Japan for the treatment of Parkinson's disease. Clinical trials with talipexole in patients with Parkinson's disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.

Originator

Curator's Comment: # Boehringer Ingelheim Pharma KG

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
5.8 null [pKi]
7.0 null [pKi]
7.43 null [pKi]
7.09 null [pKi]
7.37 null [pKi]
6.48 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Intranasal application of the alpha2-adrenoceptor agonist BHT-920 produces decongestion in the cat.
2001 Nov-Dec
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002 Nov
Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.
2004 May 1
Drug treatment of Parkinson's disease.
2004 Sep
Pre-junctional alpha2-adrenoceptors modulation of the nitrergic transmission in the pig urinary bladder neck.
2007
Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction.
2010 May
[Dopaminergic neuroprotection and reconstruction of neural network tiara].
2010 Oct
Patents

Patents

Sample Use Guides

Initially 0.2 or 0-4 mg/day, increased by 0.4 mg every week (usual maintenance dosage 1.2 to 3.6 mg/day) Below 0.8 mg/day, once a day; 0.8 to 1.2 mg/day, twice a day; over 1.2 mg/day, 3 times a day
Route of Administration: Oral
In Vitro Use Guide
Talipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c in the cytosolic fraction of human neuroblastoma SH-SY5Y cells
Name Type Language
TALIPEXOLE DIHYDROCHLORIDE
MI  
Common Name English
TALIPEXOLE HYDROCHLORIDE
JAN   MART.   WHO-DD  
Common Name English
TALIPEXOLE DIHYDROCHLORIDE [MI]
Common Name English
Talipexole hydrochloride [WHO-DD]
Common Name English
TALIPEXOLE HYDROCHLORIDE [JAN]
Common Name English
TALIPEXOLE HYDROCHLORIDE [MART.]
Common Name English
TALIPEXOLE HCL
Common Name English
Code System Code Type Description
CAS
36085-73-1
Created by admin on Fri Dec 15 15:28:52 GMT 2023 , Edited by admin on Fri Dec 15 15:28:52 GMT 2023
PRIMARY
PUBCHEM
104870
Created by admin on Fri Dec 15 15:28:52 GMT 2023 , Edited by admin on Fri Dec 15 15:28:52 GMT 2023
PRIMARY
SMS_ID
100000090502
Created by admin on Fri Dec 15 15:28:52 GMT 2023 , Edited by admin on Fri Dec 15 15:28:52 GMT 2023
PRIMARY
FDA UNII
9R6E1D8H1O
Created by admin on Fri Dec 15 15:28:52 GMT 2023 , Edited by admin on Fri Dec 15 15:28:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID20189669
Created by admin on Fri Dec 15 15:28:52 GMT 2023 , Edited by admin on Fri Dec 15 15:28:52 GMT 2023
PRIMARY
EVMPD
SUB04670MIG
Created by admin on Fri Dec 15 15:28:52 GMT 2023 , Edited by admin on Fri Dec 15 15:28:52 GMT 2023
PRIMARY
MERCK INDEX
m10441
Created by admin on Fri Dec 15 15:28:52 GMT 2023 , Edited by admin on Fri Dec 15 15:28:52 GMT 2023
PRIMARY Merck Index